Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27405566 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL1920411 | 0.98 | SLC6A4 (0.49) | SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL30858705 | 0.98 | SLC6A4 (0.49) | SLC6A4SLC6A3 | |
| SCHEMBL16107911 | 0.87 | FPR1 (0.54) | SLC6A4SLC6A3 | |
| SCHEMBL3828022 | 0.87 | FPR1 (0.54) | SLC6A4SLC6A3 | |
| SCHEMBL13979149 | 0.87 | FPR1 (0.54) | SLC6A4SLC6A3 | |
| SCHEMBL14353917 | 0.85 | SLC6A2 (0.46) | SLC6A4SLC6A3 | |
| SCHEMBL16033453 | 0.85 | SLC6A3 (0.50) | SLC6A4SLC6A3 | |
| SCHEMBL18700413 | 0.85 | SLC6A2 (0.46) | SLC6A4SLC6A3 | |
| SCHEMBL16033454 | 0.85 | SLC6A3 (0.50) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039622-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-20110245500-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2011-10-06 | — | — | US | disclosed |
| US-20110237795-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2011-09-29 | — | — | US | disclosed |
| US-20110224219-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2011-09-15 | — | — | US | disclosed |
| EP-2350060-A2 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd (KR) | 2011-08-03 | — | — | EP | disclosed |
| EP-1716135-B1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LTD (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20100120783-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCE LTD. (KR) | 2010-05-13 | — | — | US | disclosed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237795-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | SLC6A4 367/4885SLC6A3 297/4885 |
| US-20110245500-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | SLC6A4 367/4885SLC6A3 297/4885 |
| US-20100120783-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | SLC6A4 367/4885SLC6A3 297/4885 |
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | SLC6A4 1052/4885SLC6A3 1135/4885 |
| US-20110224219-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | SLC6A4 367/4885SLC6A3 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.